Advair and Flovent on CRP in COPD

Phase 4, randomised, double-blind trial of fluticasone propionate in chronic obstructive pulmonary disease (COPD), sponsored by University of British Columbia. Primary endpoint: C-reactive protein at 4 weeks. Status: unknown.